Table 1

Baseline characteristics of all randomised patients*

CharacteristicMeasure
Demographics (±SD)
 Age, year52±9
 Male/female, n69/16
 BMI, kg/m234±7
 Waist circumference, cm112±21
 Neck circumference, cm44±5
 Office SBP, mm Hg147±12
 Office DBP, mm Hg92±8
 HR71±10
Ambulatory BP (±SD)
 Wake mean SBP, mm Hg148.0±15.2
 Sleep mean SBP, mm Hg126.5±17.6
 24-Hour mean SBP, mm Hg143.8±17.9
 Wake mean DBP, mm Hg91.1±11.7
 Sleep mean DBP, mm Hg75.8±011.7
 24-Hour mean DBP, mm Hg88.1±13.2
 Wake mean HR, bpm77.1±13.0
 Sleep mean HR, bpm67.4±11.7
 24-Hour mean HR, bpm75.2±13.4
 Non-dippers†, %24.7
Medical history, n (%)
 Hypertension77 (91)
 Type 2 diabetes8 (9)
 Hypercholesterolaemia15 (18)
 Stroke1 (1)
 Heart disease6 (7)
 Current smoker9 (11)
 Ex-smoker31 (37)
Antihypertensives at screening, n (%)
 Not prescribed30 (35)
 Prescribed55 (65)
Number of classes of antihypertensives that patients were taking apart from ACE inhibitors or ARB at randomisation, n (%)
 042 (49)
 136 (42)
 27 (8)
PSG values (±SD)
 AHI, events/hour48±23
 REM AHI, events/hour48±23
 NREM AHI, events/hour47±26
 ODI −3%, events/hour42±25
 Minimum SaO2, %76±12
 ESS10±5
 FOSQ16±3
Clinical laboratory test values (±SD)
 Creatinine, μmol/L81.5±12.5
 Fasting glucose, mmol/L5.8±1.1
 Total cholesterol, mmol/L5.2±1.0
 Triglycerides, mmol/L2.0±1.2
  • *Plus-minus values are mean±SD as noted.

  • †Non-dipping status was determined by (sleep SBP/wake SBP)×100 ≤10%.

  • AHI, apnoea-hypopnoea index; ARB, angiotensin receptor blocker; BMI, body mass index (weight in kilograms divided by the square of the height in metres); BP, blood pressure; DBP, diastolic blood pressure; ESS, Epworth Sleepiness Scale; FOSQ, Functional Outcomes Sleep Questionnaire; HR, heart rate; NREM, non-rapid eye movement; ODI, oxygen desaturation index; PSG, polysomnogram; SaO2, oxygen saturation level as measured by pulse oximetry; SBP, systolic blood pressure.